OI
HAE icon

Oakbrook Investments’s Haemonetics HAE Stock Holding History

Oakbrook Investments’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,550
Closed -$408K – 270
2019
Q4 		$408K Hold
3,550
– – 0.08% 383
2019
Q3 		$448K Sell
3,550
-100
-3% -$12.7K 0.03% 407
2019
Q2 		$439K Buy
+3,650
New +$359K 0.03% 420
2018
Q4 		– Sell
-2,000
Closed -$229K – 608
2018
Q3 		$229K Buy
+2,000
New +$207K 0.01% 599

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Oakbrook Investments's HAE Position: Q1 2020 in Review

Oakbrook Investments sold out of Haemonetics (HAE) in Q1 2020, closing a stake of 3,550 shares — an estimated $408K sold.

Oakbrook Investments first reported a position in HAE in Q3 2018 and held it in 4 quarters. The position peaked at $448K in Q3 2019. 269 funds tracked by Wall St. Rank hold HAE as of Q1 2020.

  • Oakbrook Investments reported no remaining Haemonetics position as of Q1 2020 after selling out during the quarter.
  • Oakbrook Investments sold 3,550 Haemonetics shares in Q1 2020, an estimated $408K.
  • Oakbrook Investments first reported a position in Haemonetics in Q3 2018 and held it in 4 quarters.
  • Oakbrook Investments's Haemonetics position peaked at $448K in Q3 2019.
  • 269 funds tracked by Wall St. Rank held Haemonetics as of Q1 2020.

Based on Oakbrook Investments's 13F filing for Q1 2020, filed 22 Apr 2020.